CombiGene receives a second payment of EUR 1.21 million from Horizon 2020

May 15, 2018, CombiGene announced that Horizon 2020, the EU framework program for research and development, will invest EUR 3.36 million in CombiGene’s ongoing development and commercialization of the company’s gene therapy project focusing on hard-to-treat epilepsy. The upfront payment amounted to EUR 1.51 million. The second payment amounts to EUR 1.21 million and has now been payed after a careful examination of the project by EU and their external reviewer.

“The payment from Horizon 2020 is a confirmation of the progress that has been made within the CG01 project, not least the work we are doing together with CGT Catapult to develop a commercially viable production method”, says Karin Agerman, Karin Agerman, Chief Research and Development Officer at CombiGene. “In addition to getting our report approved and the money paid to our account, we have also received positive feedback and valuable recommendations from Horizon 2020’s external reviewer. That our epilepsy project is one of the projects that Horizon 2020 has chosen to invest in means a lot for CombiGene. In addition to the capital that is provided into the project, it is also a significant seal of excellence of our development work and commercial potential.”

Share